Keystone Symposia

Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2019


Here are the related meetings in 2021:
Neurodegenerative Diseases: Genes, Mechanisms and Therapeutics - RESCHEDULING TO VIRTUAL (Z3)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)


Organizer(s) Valina L. Dawson, Joseph W. Lewcock and Fred H. Gage
June 16—20, 2019
Keystone Resort • Keystone, CO USA
Discounted Abstract Deadline: Feb 13, 2019
Abstract Deadline: Mar 13, 2019
Scholarship Deadline: Feb 13, 2019
Discounted Registration Deadline: Apr 16, 2019

Sponsored by BioLegend, Inc., Biogen, BlueRock Therapeutics, Genentech, Inc., Ionis Pharmaceuticals, Inc., Roche and Takeda Pharmaceutical Company Limited


Summary of Meeting:
The global burden of neurodegenerative disease is staggering and growing at an alarming rate as the population ages. While Alzheimer’s disease and related dementias, as well as, Parkinson’s disease and related disorders, account for the majority of those afflicted, there are also less common but equally devastating diseases. Technical and conceptual advances are revealing disease mechanisms and providing new therapeutic opportunities. Misfolded proteins have been understood to be at the center of neurodegenerative diseases but recently there is an appreciation that these misfolded proteins may serve as seeds to template the misfolding of normal proteins, that transmission of these seeds may underlie disease progression, and that there may be different strains of these seeds with differential toxicities. Biophysical analysis of these proteins reveals a role for phase transition and liquid demixing of these intrinsically disordered proteins. Synaptic loss is an important feature of neurodegeneration which may occur long before neuronal loss, but be critically important in disease presentation and loss of function. Glia and immune activation contribute to neurodegeneration and synaptic loss, and must be understood and controlled if the disease process is to be tempered or stopped. This conference aims to address the current state of knowledge in these emerging area and to provide advanced discussion of these topics; the opportunity for interaction between scientists from different fields of research will foster new collaborations that may lead to new therapeutic opportunities to combat the coming crisis and provide medical care for those suffering from neurodegenerative diseases.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, June 16 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, June 20 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, June 21 in order to fully experience the meeting.

SUNDAY, JUNE 16

16:00—20:00
Arrival and Registration

Longs Peak Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Longs Peak Foyer

MONDAY, JUNE 17

07:30—08:30
Breakfast

Colorado Rockies Ballroom
08:30—09:30
Welcome and Keynote Address

Grays/Longs Peak
* Fred H. Gage, The Salk Institute for Biological Studies, USA

Marc Tessier-Lavigne, Stanford University, USA
Molecular Control of Axon Degeneration in Development, Disease and Adult Plasticity

08:30—09:30
Welcome and Keynote Address

Quandary Peak
* Richard Daneman, University of California, San Diego, USA

* Dorothy Schafer, University of Massachusetts Medical School, USA

Li-Huei Tsai, Massachusetts Institute of Technology, USA
Neuron-Glia Interaction in Health and Disease

09:30—11:45
Aggregation Mediated Toxicity

Grays/Longs Peak
* Xiaobo Mao, Johns Hopkins University, USA

Rudolph E. Tanzi, Massachusetts General Hospital, USA
Amyloid Beta Organoid Model

Coffee Break

Valina L. Dawson, Johns Hopkins University School of Medicine, USA
Alpha Synuclein Toxicity

Patrik Verstreken, KU Leuven, Belgium
Tau Toxicity at the Synapse

Thomas Brannstrom, Umea University Hospital, Sweden
Short Talk: Transmissibility of SOD1 Prion Strains Between Mice Expressing Different Mutant Human SOD1s

09:30—12:00
Neuronal Response to Injury

Quandary Peak
* David M. Holtzman, Washington University, USA
TREM2 Function Regulates Aβ linked Tau Seeding and Spreading in Neuritic Plaques

Coffee Break

Eric J. Huang, University of California, San Francisco, USA
Neuron-Glia Interaction in Human Germinal Matrix: Implications in Neurodevelopmental Disorders

* Marc R. Freeman, Oregon Health & Science University, USA
Mechanisms of Axon Degeneration

Katie Ennis, Biogen, USA
Short Talk: The Cytokine Receptor Fn14 is Required for Hippocampal Synaptic Plasticity Deficits that Occur Following Acute Ischemic Stroke

Lucas Cheadle, Harvard Medical School, USA
Short Talk: Sensory Experience Engages Microglia-to-Neuron Cytokine Signaling to Remodel Developing Synapses

11:45—17:00
On Own for Lunch

11:45—13:00
Poster Setup

Colorado Rockies Ballroom
13:00—22:00
Poster Viewing

Colorado Rockies Ballroom
15:00—16:30
Workshop 1

Grays/Longs Peak
* David V. Hansen, Genentech, Inc., USA

Michael Henderson, University of Pennsylvania, USA
Using Quantitative Pathology Mapping and Network Modeling to Understand α-Synuclein Spread

Sang Su Kwak, Genetics and Aging Research Unit, Massachusetts General Hospital, USA
Amyloid-β 42/40 Ratio Drives Tau Pathology in 3D Human Neural Cell Culture Models of Alzheimer's Disease

Evan T. Lester, University of Colorado, USA
Interactions between RNA and Tau in Models of Frontotemporal Dementia

Sílvia Porta, Center for Neurodegenerative Disease Research, USA
Patient-Derived Frontotemporal Lobar Degeneration Brain Extracts Induce Formation and Spreading of TDP-43 Pathology in vivo

Stephanie K. See, University of California, San Francisco, USA
Identification of Cellular Mechanisms that Control α-Synuclein Aggregation Using a CRISPRi/a Functional Genomics Platform

Meghan Kerrisk Campbell, Alkahest, USA
A Therapeutic Human Plasma Fraction Enhances Cognitive Function in Aging and Neurodegenerative Disease through Multiple Mechanisms of Action

14:30—16:30
Workshop 1: Modulating Microglia Inflammatory Signaling

Quandary Peak
* Kim N. Green, University of California, Irvine, USA

* Iben Lundgaard, University of Lund, Sweden

Ying Cao, Peking University, China
Transcriptional Mechanism of IRF8 and PU.1 Governs Microglial Activation in Neurodegenerative Condition

Rouven Schulz, Institute of Science and Technology Austria, Austria
Topological Classification of Microglia

Yajing Xu, University College London, UK
Microglia Mediate Restructuring of Spinal Somatosensory Circuits During Normal Postnatal Development and After Injury

Youtong Huang, University of California, San Diego / Salk Institute, USA
Investigating Microglial TAM Receptors as Modulators of Alzheimer’s Pathology

Guy C. Brown, University of Cambridge, UK
Blocking the Microglial P2Y6 Receptor Prevents Microglial Phagocytosis of Neurons and Synapses, and Prevents Neurodegeneration Induced by Neuroinflammation, Beta Amyloid, TAU and Ageing in vivo

Monique S. Mendes, University of Rochester, USA
In vivo Imaging of Microglial Self-Renewal and Maturation in the Adult Mouse Brain

Nicole Vo, University of Washington, USA
CD33 and CD45 interaction in AD

Sanda Mimouna, Hospital for Special Surgery, USA
The Role of Transcriptional Coregulator GRIP1 in Myeloid Cells in Neuroinflammation

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Transmission and Spread of Disease Pathology

Grays/Longs Peak
* Karen Hsiao Ashe, University of Minnesota, USA

Xiaobo Mao, Johns Hopkins University, USA
The Mechanism of Pathological alpha-synuclein Transmission

John Collinge, University College London, UK
Prion Neurodegeneration: Towards an Effective Treatment and its Relevance for Alzheimer’s Disease

Karina Fog, H. Lundbeck A/S, Denmark
Alpha-Synuclein Antibodies as Therapeutics in Synucleinopathies – How Antibodies Affect Cellular Handling of Misfolded alpha-synuclein

Amanda Engstrom, Emory University, USA
Short Talk: Pathological Tau Induces Neurodegeneration Through the Sequestration and Inhibition of LSD1 Function

Xuyuan Kuang, Rutgers University, USA
Short Talk: Association of Transmissive PolyQ Aggregates with Lipid Vesicles and Its Implications in Mutant Huntingtin Seeding

17:00—19:00
Astrocytes

Quandary Peak
Michael V. Sofroniew, University of California, Los Angeles, USA
Astrocyte Roles in Repair and Regeneration

* Jin-Moo Lee, Washington University, USA
Astrocytosis and Amyloid Plaque Pathogenesis

* Cagla Eroglu, Duke University Medical Center, USA
How do Glia Sculpt Synaptic Circuits?

Blanca Diaz Castro, University of Edinburgh, UK
Striatal Astrocytes: Identity, Form, Function and Roles in Huntington’s Disease

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Colorado Rockies Ballroom
19:30—22:00
Poster Session 1

Colorado Rockies Ballroom

TUESDAY, JUNE 18

07:30—08:30
Breakfast

Colorado Rockies Ballroom
08:30—11:45
New Therapeutic Opportunities

Grays/Longs Peak
* Joseph W. Lewcock, Denali Therapeutics, USA

Frank Rigo, Ionis Pharmaceuticals, USA
RNA Targeting Therapeutics for the Treatment of Neurodegenerative Diseases

Eric J. Huang, University of California, San Francisco, USA
Microglia Toxicity and TDP-43 Proteinopathy in Neurodegeneration

Coffee Break

Don W. Cleveland, University of California, San Diego, USA
Gene Silencing Therapy for Neurodegenerative Disease

Li Gan, Weill Cornell Medicine, USA
Sex-Dimorphic Effects of Microglial Dysfunction in Neurodegeneration

Dieter Willbold, Forschungszentrum Jülich, Germany
Short Talk: First Clinical Data of the First Anti-Prionic PRI-002 that is Orally Available, Reverts Cognition Deficits, and Decelerates Neurodegeneration in Transgenic AD Mouse Models

Daniel Heinzer, University of Zurich, Switzerland
Short Talk: Whole Genome RNAi Screen Identifies Novel Regulators of PrPC as Potential Therapeutic Targets in Prion Diseases

Alessandro Sette, La Jolla Institute for Immunology, USA
Short Talk: T Cell Reactivity to Tau and Alpha-Synuclein in PD

08:30—11:45
Microglia and Innate Immunity

Quandary Peak
Dorothy Schafer, University of Massachusetts Medical School, USA
Targeting Microglia-Mediated Synapse Loss for Therapeutic Intervention in Multiple Sclerosis

Kim N. Green, University of California, Irvine, USA
Microglia Facilitate Plaque Development and Mediate the Downregulation of Synaptic Genes in Alzheimer’s Disease Mice

Coffee Break

* Anne Schaefer, Mount Sinai School of Medicine, USA
Epigenetic and Signaling Controlled Brain Region-Specific Microglia Functions

* Francisco J. Quintana, Harvard Medical School, USA
Molecular Control of Astrocyte Pathogenic Activities in MS

Serena Becchi, University of New South Wales, Australia
Short Talk: The Role of Microglia when Decision Making is Impaired by a High Fat and Sugar Diet in Rats

Manana Kutsia, Okinawa Institute of Science and Technology Graduate University, Japan
Short Talk: Importance of Microglia for Neural Tissue Regeneration in Zebrafish Model of Traumatic Brain Injury

Sandra Siegert, Institute of Science and Technology Austria, Austria
Short Talk: Sex Specific Microglia Response to Transient Reduction of Neuronal Activity

11:45—17:00
On Own for Lunch

11:45—13:00
Poster Setup

Colorado Rockies Ballroom
13:00—22:00
Poster Viewing

Colorado Rockies Ballroom
16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Developing Effective Preclinical Disease Models

Grays/Longs Peak
* Valina L. Dawson, Johns Hopkins University School of Medicine, USA

Martin Kampmann, University of California, San Francisco, USA
Elucidating Cellular Mechanisms and Therapeutic Strategies for Neurodegenerative Diseases with Multimodal CRISPR-based Genetic Screens in iPSC-Derived Neurons and Glia

Elena Cattaneo, University of Milano, Italy
Organiod Models of Triple Repeat Diseases

Fred H. Gage, The Salk Institute for Biological Studies, USA
iPSC to Study Repair and Neurodegeneration

Zhuohao He, University of Pennsylvania, USA
Short Talk: Studying Tau Transmission in AD and FTLD Using Novel Mouse Models

17:00—19:00
Blood Brain Barrier

Quandary Peak
Richard Daneman, University of California, San Diego, USA
Regulation of the Blood-Brain Barrier in Health and Disease

* Alexandre Prat, Université de Montréal, Canada
Influence of Cytokines on the Blood-Brain Barrier

* Eric V. Shusta, University of Wisconsin-Madison, USA
Modeling the Neurovascular Unit Using Human iPSCs

Sidar Aydin, University of Bern, Switzerland
Short Talk: Endothelial Antigen-Presentation Stops the Migration of CD8+ T Cells Across the Blood-Brain Barrier in Neuroinflammation

Matthew N. McCarroll, University of California, San Francisco, USA
Short Talk: An Inducible Zebrafish Model of Pineal Gland Ablation Reveals Dynamics of Neuronal Cell Death, Regeneration and Microgliosis in vivo

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Colorado Rockies Ballroom
19:30—22:00
Poster Session 2

Colorado Rockies Ballroom

WEDNESDAY, JUNE 19

07:30—08:30
Breakfast

Colorado Rockies Ballroom
08:30—11:30
Translating Therapeutics for Neurodegeneration to the Clinic

Grays/Longs Peak
* Karina Fog, H. Lundbeck A/S, Denmark

Joseph W. Lewcock, Denali Therapeutics, USA
Therapeutic Strategies Based on Human Genetics

Matthew Kennedy, Merck Research Labs, USA
Discovery and Development of LRRK2 Inhibitors

Coffee Break

David V. Hansen, Genentech, Inc., USA
Microglial Activation States in Alzheimer's Disease: Are You a (Wo)man or a Mouse?

Jeffrey L. Cleland, Orpheris, Inc., USA
Short Talk: OP-101: Human Safety and Pharmacokinetics of a Microglia-targeted Systemic Therapy for Neuroinflammation

Anna Ettorre, 4D Pharma Research Ltd., UK
Short Talk: From Screening to Pre-Clinical Efficacy of Microbiome-Derived Bacterial Strains that Modulate Neuroinflammatory and Neurodegenerative Processes in Parkinson's Disease

Garrett S. Gibbons, University of Pennsylvania, USA
Short Talk: Conformation-Selective Tau Monoclonal Antibodies as Immunotherapy Candidates for Alzheimer's Disease (AD) and Frontotemporal Lobar Degeneration-tau (FTLD-tau)

08:30—11:45
Glymphatics and Lymphatics

Quandary Peak
* Kari K. Alitalo, University of Helsinki, Finland
CNS Lymphatics

Iben Lundgaard, University of Lund, Sweden
Glymphatics

Coffee Break

Maria Lehtinen, Harvard Medical School, USA
Orchestration of Embryonic Brain Development by the Choroid Plexus

* Julie Siegenthaler, University of Colorado Denver, USA
Meningeal Fibroblast Identity and Function: New Insights from scRNA-Sequencing

Percy Griffin, Washington University in St. Louis, USA
Short Talk: Circadian Regulation of Neuroinflammation and Neurodegeneration by Rev-Erba

Celia McKee, Washington University in St. Louis, USA
Short Talk: The Astrocyte Circadian Clock Regulates Amyloid Beta Deposition and Degradation

Caio Mazucanti, NIA, National Institutes of Health, USA
Short Talk: Serotonergic Regulation of Insulin Expression & Release in Choroid Plexus

11:30—17:00
On Own for Lunch

11:30—13:00
Poster Setup

Colorado Rockies Ballroom
13:00—22:00
Poster Viewing

Colorado Rockies Ballroom
14:30—16:30
Round Table Discussion from Industry, Government and Academia - Challenges and Opportunities

Grays/Longs Peak
* Joseph W. Lewcock, Denali Therapeutics, USA

Gene W. Yeo, University of California, San Diego, USA

Matthew Kennedy, Merck Research Labs, USA

Frank Rigo, Ionis Pharmaceuticals, USA

Amir Tamiz, NINDS, National Institutes of Health, USA

Aaron D. Gitler, Stanford University School of Medicine, USA

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Molecular Mechanisms of ALS/FTD

Grays/Longs Peak
* Shanthini Sockanathan, Johns Hopkins University School of Medicine, USA

Aaron D. Gitler, Stanford University School of Medicine, USA
Expanding Mechanisms and Therapeutic Targets for Neurodegenerative Disease

Clotilde Lagier-Tourenne, Massachusetts General Hospital, USA
Molecular Mechanisms of Disease in ALS and FTD

Gene W. Yeo, University of California, San Diego, USA
Protein-RNA and Stress Granules Dysregulation in ALS

Hideyuki Takahashi, Yale University, USA
Short Talk: Progranulin Deficiency Induces Expression of Microglial TYROBP Gene Network and Differentially affects Alzheimer's disease pathologies

Evangelos Kiskinis, Northwestern University Feinberg School of Medicine, USA
Short Talk: Nucleocytoplasmic Proteomic Analysis Highlights ETF1 and Nonsense Mediated Decay as Therapeutic Targets in C9ORF72-Related ALS/FTD

17:00—19:00
Adaptive Immune Responses

Quandary Peak
Vanda A. Lennon, Mayo Clinic, USA
Astrocytic and Oligodendroglial Autoimmunity

* Daniel S. Reich, NINDS, National Institutes of Health, USA
Imaging Lesion Repair in Multiple Sclerosis

* Jorge I. Alvarez, University of Pennsylvania, USA
CNS Intrinsic Mechanisms Suppressing T Cell Driven Neuroinflammation

Keita Saeki, National Institutes of Health, USA
Short Talk: IRF8 Shapes Long-Term Endotoxin Memory in Microglia

Tiffany J. Petrisko, West Virginia University, USA
Short Talk: CXCL10-CXCR3 Axis Mediates Induction of Cerebral Hyperexcitability by Peripheral Viral Challenge

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Colorado Rockies Ballroom
19:30—22:00
Poster Session 3

Colorado Rockies Ballroom

THURSDAY, JUNE 20

07:30—08:30
Breakfast

Colorado Rockies Ballroom
08:30—11:30
Drivers of Synaptic Loss in Disease

Grays/Longs Peak
* Clotilde Lagier-Tourenne, Massachusetts General Hospital, USA

Paul F. Worley, Johns Hopkins School of Medicine, USA
Immediate Early Genes and Alzheimer’s Disease

Beth Stevens, Boston Children's Hospital, Harvard Medical School, USA
Dynamic Microglia States and Functions in Health & Disease

Coffee Break

Karen Hsiao Ashe, University of Minnesota, USA
Synaptic and Cognitive Dysfunction from Non-fibrillar Tau

Shanthini Sockanathan, Johns Hopkins University School of Medicine, USA
Control of ADAM10 α-Secretase Cleavage of Amyloid Precursor Protein by GDE2-RECK

Ryan Douglas Hallam, University of Guelph, Canada
Short Talk: Synuclein Fibrils Inhibit Synaptic Function in Cortical Neurons through Induction of Nitrosative Stress

Claire E. Le Pichon, NICHD, National Institutes of Health, USA
Short Talk: Enhancing the Benefits of DLK Inhibition in a Mouse Model of ALS by Restoring an Adaptive Neuronal Response

08:30—11:30
Oligodendrocytes and Inflammation

Quandary Peak
David H. Rowitch, University of Cambridge, UK
Neuronal Vulnerability and Multilineage Diversity in Multiple Sclerosis

* Kelly Monk, Oregon Health & Science University, USA
Molecular and Genetic Mechanisms of Myelin Formation and Repair

Coffee Break

Dimitry Ofengeim, Sanofi, USA
Understanding the Nature of Microglial Phenotypes through the Interplay of Cell Death and Inflammation

Stefan Berghoff, Max-Planck Institut for Experimental Medicine, Germany
Short Talk: Cell-Type Specific Cholesterol Synthesis Coordinates Inflammation and Remyelination in Demyelinated Lesions

Claudia Fuchs, University of Bologna, Italy
Short Talk: Loss of CDKL5 Enhances Microglia Activation: Are Neuro-Inflammatory Mechanisms Implicated in the Pathophysiology of CDKL5 Deficiency Disorder?

TrangKimberly T. Nguyen, Emory University, USA
Short Talk: Proteomic Analyses Reveal that Glia-Specific and Seizure-Protective Receptors GPR37L1 and GPR37 Regulate S100A Calcium-Binding Protein Expression and Secretion

11:30—17:00
On Own for Lunch

15:00—16:30
Workshop 2

Grays/Longs Peak
* Katerina Akassoglou, University of California, San Francisco, USA

Irina Alexandra Leaf, Biogen, USA
Reverse Translational Multimodal Approach to Identify CSF Signatures Associated with Disease Progression in MS

Chelsey J. LeBlang, Boston University School of Medicine, USA
Modulation of the Inflammatory Response by the RNA-binding Protein TIA1 in the P301S Mouse Model of Tauopathy

Yihang Li, Dana-Farber Cancer Institute, USA
SARM1 Interacts with the Bclw/IP3R Pathway in Paclitaxel-Induced Axon Degeneration

Michael A. Lodato, Boston Children's Hospital, USA
Single-Cell, Whole-Genome Sequencing Reveals Mechanisms of DNA Damage and Somatic Mutation in the Human Brain during Aging and in Neurodegeneration

Michaela O. Lunn, Carleton University, Canada
Contribution of Lrrk2 to the Modulation of Host Immunity during Infection

Jing Yang, Peking University, China
Local Degeneration of Catecholaminergic Axons Acts as the Protective Mechanism in Colitis

Samara Reck-Peterson, University of California, San Diego, USA
A Structural and Mechanistic Model for the Regulation of LRRK2’s Interaction with Microtubules

14:30—16:30
Workshop 2: Astrocyte-Microglia Crosstalk during Inflammation

Quandary Peak
* Blanca Diaz Castro, University of Edinburgh, UK

Lilianne Barbar, New York Stem Cell Foundation Research Institute, USA
Developing in vitro Models of Neurodegeneration Based on Human iPSC-Derived Astrocytes

Cristina Gutierrez-Vazquez, Harvard Medical School, USA
EphrinB3 Signaling Promotes Pathogenic Activities in Astrocytes during Central Nervous System Inflammation

Weikang Cai, Joslin Diabetes Center, USA
Insulin Signaling-Dependent ATP Release from Astrocytes is Important for Dopamine Release and Depressive-Like Behavior

Elena Blanco-Suarez, The Salk Institute for Biological Studies, USA
Astrocyte-Secreted Chrdl1 Promotes Synapse Maturation and Limits Synaptic Plasticity through GluA2-AMPAR Increase

Martín M. Riccomagno, University of California, Riverside, USA
Novel Combinatorial Approaches to Selectively Target Reactive Astrocytes

Kun Leng, University of California, San Francisco, USA
Mapping Pathways Controlling the Reactive State of Astrocytes through CRISPRi Loss-of-Function Screening and Single-Cell RNA-Seq

Deepa Jonnalagadda, Sanford Burnham Prebys Medical Discovery Institute, USA
Sphingosine 1-Phosphate Signaling Effects in Immediate-Early Astrocytes (ieAstrocytes)

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—18:45
Glial Contributors to Neurodegeneration

Grays/Longs Peak
* Beth Stevens, Boston Children's Hospital, Harvard Medical School, USA

Mathew M. Blurton-Jones, University of California, Irvine, USA
Development of a Chimeric Model to Study and Manipulate Human Microglia in vivo

Katerina Akassoglou, University of California, San Francisco, USA
Neurovascular Interactions: Mechanisms, Imaging, Therapeutics

Sandeep Robert Datta, Harvard Medical School, USA
The MS4A Gene Family in Alzheimer’s Disease

Anastasia Efthymiou, Icahn School of Medicine at Mount Sinai, USA
Short Talk: Investigating the Effect of the MS4A locus on Alzheimer's Disease Risk

17:00—18:45
Hot Topics

Quandary Peak
Erik M. Ullian, University of California, San Francisco, USA
Novel Three-Dimensional Astrocyte-Containing Organoids Recapitulate Key Aspects of Human Neurodegenerative Disease

* Long-Jun Wu, Mayo Clinic, USA
Neuronal Network Activity Controls Microglial Process Surveillance in Awake Mice via Norepinephrine Signaling

* Yi Ren, Florida State University, USA
The Inflammatory Mechanisms Involved in Myelin-Debris-Induced Pathological Changes in Neural Injury

Julia A. Kuhn, Genentech, Inc., USA
Short Talk: Sex Differences in Microglial Contributions to Pain

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions

Grays/Longs Peak
Valina L. Dawson, Johns Hopkins University School of Medicine, USA

Joseph W. Lewcock, Denali Therapeutics, USA

Fred H. Gage, The Salk Institute for Biological Studies, USA

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions

Quandary Peak
Vanda A. Lennon, Mayo Clinic, USA

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Colorado Rockies Ballroom
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Colorado Rockies Ballroom

FRIDAY, JUNE 21

 
Departure


*Session Chair †Invited, not yet responded.


We gratefully acknowledge support for this conference from:


Directors' Fund

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.

Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:

Biogen BioLegend, Inc.
BlueRock Therapeutics Genentech, Inc.
Ionis Pharmaceuticals, Inc. Roche
Takeda Pharmaceutical Company Limited
 

We gratefully acknowledge additional support from these exhibitors at this conference:

Antibodies Incorporated Illumina
Proteintech Group
 
Please stop by to meet these exhibitors during the conference.

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13NS111936-01

Funding for this conference was made possible (in part) by 1R13NS111936-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We gratefully acknowledge additional support for this conference from:

American Society of Gene & Cell Therapy (ASGCT) GeneTex, Inc.

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Denali Therapeutics Inc.


Genentech, Inc.


H. Lundbeck A/S


Ionis Pharmaceuticals, Inc.


Merck & Co., Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179